D-Cycloserine: clinical situation

Studies have shown that this product is mainly used for the infection of first-line anti-tuberculosis drug-resistant Mycobacterium tuberculosis and patients who cannot tolerate other anti-tuberculosis drugs. It is one of the main second-line drugs, usually in combination. Clinical trials have shown that the combination of cycloserine and isoniazid and rifampicin can improve patient survival.

Second-line drugs are relatively weak, usually for more than 2 years.

India's 2033 sputum specimens (6099) reviewed between 521 (25.6%) patients (335 males and 186 females; aged 11 to 75 years old) with positive culture and sensitivity from 1991 to 1995. Acid-fast bacilli (AFB) response. Our study related to drug resistance patterns: isoniazid 15%, rifampicin 66.8%, pyrazinamide 72.2%, ethambutol 8.4%, streptomycin 53.6%, D-cycloserine 39.2%, streptomycin 25.1% and ethanethioamide 65.3%.

In 1998, the Department of Tuberculosis Research in India reported that resistance to isoniazid, rifampicin, and streptomycin in more than 200 patients was 72%, 49%, and 37%, respectively, while resistance to D-cycloserine and ethionamide was observed. Only 1%. Clinical experience has proven that pediatric tuberculosis chemotherapy works well. According to the efficacy of the drug and the magnitude of the toxicity.

The evaluation of anti-tuberculosis drugs is as follows:
1, first class, isoniazid, and rifampicin; first class is streptomycin, pyrazinamide, ethionamide, and ethambutol.
2, second class: ring serine, kanamycin, ciprofloxacin, sodium p-aminosalicylate, and zirconia.
3. The third grade is thiourea.

There have been few clinical reports on the treatment of tuberculosis since 1999. More are reports on phobia. In 2006, a tuberculosis research department in Osaka, Japan reported that pregnant women had a significant effect on the treatment of multidrug-resistant tuberculosis (MDR-TB) with second-line drugs such as serine, ethambutol and pyrazinamide, and the health of newborn babies.

In 2006, a hospital in the capital of Spain used levofloxacin and D-cycloserine for 17 patients with multi-drug resistant tuberculosis who were not infected with HIV (68%) who were cured after 24 months of follow-up treatment without recurrence or death. The Iranian Tuberculosis Infectious Diseases Research Department reported in 2005 that the use of D-cycloserine in the treatment of MDR-TB can achieve a healing effect.